Concepedia

Author

Charlotte Gaskell

University of BirminghamORCID

Also Known As

Charlotte Gaskell, Gaskell, C

24

Publications

473

Citations

7

H-Index

13

Concepts

All Affiliations

University of BirminghamCancer Research UK Clinical Trials UnitUniversity of OxfordOxford University Hospitals NHS TrustUniversity Hospitals Birmingham NHS Foundation Trust
CG

About

Charlotte Gaskell is an author at University of Birmingham specializing in medicine, clinical trials, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

135

2

Health Sciences

1

1

78

3

Pharmacology

1

1

78

4

Cancer Metabolism

1

1

78

5

Cancer Therapeutics

1

1

78

Charlotte Gaskell

×

7

Publications

453

Citations

7

H-Index

YearCitations

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe,

Nature Medicine

2023

124

Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell,

BMC Cancer

2021

97

Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

Jennifer Pascoe, Aimee E. Houlton, Charlotte Gaskell,

Research Square (Research Square)

2021

78

Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial

Pamela Kearns, Stefan Siebert, Michelle Willicombe,

SSRN Electronic Journal

2021

74

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Tonny Veenith, Daniel Slade, Charlotte Gaskell,

UCL Discovery (University College London)

2022

57

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

Mark W. Drummond, Charlotte Gaskell, Claire Harrison,

Blood

2020

13

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata

Penella J. Woll, Piers Gaunt, Charlotte Gaskell,

British Journal of Cancer

2023

10

Page 1